What is it about?

Ovarian cancer is often treated with PARP inhibitors such as olaparib, but many patients eventually stop responding to these drugs. In this study, we grew ovarian cancer cells in the laboratory that became resistant to olaparib and compared them with drug-sensitive cells. We found that a protein called HNF4G was higher in the resistant cells. Increasing HNF4G made cancer cells more resistant to olaparib, while reducing HNF4G made resistant cells more sensitive to the drug. The effect appeared to work through the PI3K–AKT signaling pathway. In mice, tumors with reduced HNF4G grew more slowly during olaparib treatment. These findings suggest that HNF4G may be a useful marker or target for future studies on olaparib-resistant ovarian cancer, but more research is needed before clinical use.

Featured Image

Why is it important?

PARP inhibitors like olaparib are standard maintenance therapy for ovarian cancer, but many patients develop resistance and options afterward are limited. Our study is the first to link HNF4G to olaparib resistance in ovarian cancer. We show HNF4G is higher in resistant cells, that increasing it enhances resistance, and that reducing it re-sensitizes cells to olaparib via the PI3K–AKT pathway, with validation in mice. This is timely as PARPi use expands and unique because HNF4G was not previously implicated in PARPi resistance. It may guide future biomarker and combination-target studies, though clinical validation is still needed.

Perspectives

This project began with a problem we see in the clinic: patients with ovarian cancer often respond well to olaparib at first, but many later relapse, and we still lack good options for them. As a gynecologic oncology researcher, that gap is what motivated me to build the resistant cell model and ask what changes inside the tumor. What surprised me most was how strong the HNF4G effect turned out to be reducing it made resistant cells sensitive again, and the mouse experiments supported the cell data. I am grateful to my co-authors and to the patients whose samples and clinical experience ultimately motivate this work. I hope this paper encourages other groups to look at HNF4G and the PI3K–AKT axis as testable hypotheses for overcoming PARPi resistance, and I hope it eventually contributes, even in a small way, to better treatment for women with recurrent ovarian cancer

Ying Dong
The Second Affiliated Hospital of Kunming Medical University

Read the Original

This page is a summary of: Overexpression of HNF4G can Increase the Resistance of Ovarian Cancer Cells to Olaparib, Current Cancer Drug Targets, October 2025, Bentham Science Publishers,
DOI: 10.2174/0115680096410121250926110350.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page